Inquiry Basket
Loading ......
Accurate and timely diagnosis of hantavirus infection is essential for appropriate patient management, epidemiological surveillance, and outbreak investigation. Because the early clinical presentation of hantavirus diseases (HFRS and HPS) overlaps with many other febrile illnesses including influenza, dengue, leptospirosis, and bacterial sepsis, laboratory confirmation is critical for guiding treatment decisions and triggering public health responses. Diagnostic approaches for hantavirus infections include serological assays to detect virus-specific antibodies, molecular methods to detect viral RNA, and antigen detection techniques. The choice of diagnostic method depends on the stage of infection, the clinical presentation, and available laboratory resources.
Figure 1. Diagnostic algorithm for hantavirus infection detection. (Rio et al., 2024)
Serological testing forms the foundation of hantavirus diagnosis in most clinical settings worldwide. Because antibodies develop rapidly following infection and persist for months to years, serological assays provide a reliable means of confirming both acute and past infections. The kinetics of the antibody response differ between Old World and New World hantaviruses, but in general, IgM antibodies appear within 3 to 7 days of symptom onset, followed by IgG seroconversion within 7 to 14 days. A fourfold or greater rise in IgG titer between acute and convalescent phase sera provides definitive evidence of recent infection.
ELISA is the most widely used method for hantavirus serodiagnosis due to its high sensitivity, throughput capacity, and ease of use. IgM capture ELISA (MAC-ELISA) is the preferred method for acute-phase diagnosis, as IgM antibodies typically appear within the first week of illness and persist for 2 to 6 months. IgG ELISA is useful for seroepidemiological studies and confirming past infection. Recombinant nucleocapsid (N) protein is commonly used as the capture antigen due to its high immunogenicity and strong conservation across hantavirus species, enabling broad detection of antibodies against multiple hantaviruses with a single assay format.
Modern hantavirus ELISA platforms have evolved to include multiplex formats that can simultaneously detect antibodies against multiple hantavirus species, enabling clinicians to not only confirm infection but also identify the likely causative virus. The use of recombinant glycoprotein Gn and Gc antigens in ELISA improves species specificity compared to N protein-based assays, which tend to show extensive cross-reactivity among hantaviruses due to the conserved nature of the nucleocapsid protein.
Indirect immunofluorescence assays use hantavirus-infected Vero E6 cells or recombinant antigen-expressing cells to detect virus-specific antibodies in patient serum. While IFA offers good sensitivity and can differentiate antibody responses to different hantavirus species by using cells infected with distinct virus types, it requires specialized fluorescence microscopy equipment and trained personnel for interpretation. The subjective nature of IFA reading introduces inter-operator variability, making it less suitable for high-throughput screening or field deployment. Nevertheless, IFA remains an important confirmatory tool in reference laboratories.
Western blot analysis using recombinant hantavirus proteins (N protein, Gn, Gc) provides confirmatory serological evidence and can help identify specific antibody responses to individual viral proteins. The distinct molecular weights of the nucleocapsid protein (approximately 48 kDa), Gn (approximately 72 kDa), and Gc (approximately 55 kDa) allow clear band identification. Strip immunoblot assays (SIA) offer a simplified format suitable for smaller laboratories and can distinguish between hantavirus species based on antibody reactivity patterns to species-specific recombinant antigens.
Table 1. Comparison of Serological Diagnostic Methods for Hantavirus Infection
| Method | Target | Sensitivity | Turnaround | Best Use |
| IgM ELISA | Anti-N IgM | High (90-98%) | 2-4 hours | Acute diagnosis |
| IgG ELISA | Anti-N IgG | High (95-99%) | 2-4 hours | Serosurveys, past infection |
| IFA | IgM/IgG | Moderate-High | 4-6 hours | Species differentiation |
| Western Blot | IgG to N/Gn/Gc | High | 1-2 days | Confirmatory testing |
| Neutralization test | Neutralizing Ab | Very High | 5-7 days | Research, typing |
Figure 2. Serological detection of hantavirus-specific antibodies by ELISA. (Rio et al., 2024)
Reverse transcription polymerase chain reaction (RT-PCR) is the primary molecular method for detecting hantavirus RNA in clinical specimens. RT-PCR is most useful during the early acute phase of infection, before seroconversion, when viral RNA is readily detectable in blood and plasma. Conventional RT-PCR, real-time quantitative RT-PCR (qRT-PCR), and nested RT-PCR protocols have been developed for major pathogenic hantavirus species. The S segment, encoding the nucleocapsid protein, is the most commonly targeted genomic region due to its high conservation, while M segment primers provide better species discrimination based on glycoprotein sequence diversity. Specimen collection timing is critical for molecular detection: viral RNA levels are highest during the febrile prodrome and decline rapidly after the onset of the immune response, meaning that RT-PCR sensitivity decreases substantially after day 7 to 10 of illness.
Quantitative RT-PCR offers the additional advantage of viral load measurement, which can serve as a prognostic indicator. Studies have shown that higher viral loads in the acute phase correlate with more severe disease outcomes in both HFRS and HPS patients. This information can help clinicians identify patients who may require more intensive monitoring and supportive care, including early initiation of renal replacement therapy or mechanical ventilation.
Next-generation sequencing (NGS) and metagenomic approaches have emerged as powerful tools for identifying novel hantavirus species and investigating outbreak strains. These methods are particularly valuable when conventional assays fail to identify the infecting virus or when surveillance studies aim to characterize hantavirus diversity in rodent populations. Whole-genome sequencing of clinical isolates also supports molecular epidemiological investigations by enabling phylogenetic comparison of outbreak strains with known reference sequences.
Lateral flow immunochromatographic assays provide point-of-care hantavirus diagnosis within 15 to 30 minutes, making them valuable for field investigations and resource-limited settings. These tests typically detect IgM and IgG antibodies simultaneously using recombinant N protein as the capture antigen. While rapid tests offer lower sensitivity compared to laboratory-based ELISA, they enable immediate clinical decision-making and triage of suspected cases in outbreak settings. Recent advances in lateral flow technology, including the integration of fluorescent labels and smartphone-based readers, have improved sensitivity to approach that of conventional ELISA while retaining the simplicity and speed of the rapid test format.
Point-of-care molecular testing is another emerging frontier in hantavirus diagnostics. Portable isothermal amplification platforms using recombinase polymerase amplification (RPA) or loop-mediated isothermal amplification (LAMP) can detect hantavirus RNA in under 30 minutes without the need for thermocycling equipment. These technologies hold particular promise for deployment in rural health centers in endemic regions where laboratory infrastructure is limited but rapid diagnosis is urgently needed to guide patient management and trigger public health investigations.
Several challenges complicate hantavirus diagnosis. The broad antigenic cross-reactivity of the nucleocapsid protein among different hantavirus species can make species-level identification difficult using serological methods alone. Plaque reduction neutralization tests (PRNT) remain the gold standard for species-specific antibody identification but require BSL-3 or BSL-4 containment facilities and 5 to 7 days to complete, limiting their use to reference laboratories. Additionally, the geographic overlap of multiple hantavirus species in regions such as Southeast Asia and South America necessitates diagnostic panels that can detect and differentiate multiple viruses simultaneously.
For researchers and diagnostic developers, Creative Diagnostics provides a comprehensive range of hantavirus research reagents to support assay development and validation, including recombinant nucleocapsid proteins and glycoproteins from major pathogenic hantavirus species (HTNV, PUUV, SEOV, SNV, ANDV), species-specific monoclonal antibodies, and validated ELISA kits for IgM and IgG detection. These reagents are produced under strict quality control standards to ensure consistent performance in diagnostic applications.
View more Hantavirus ELISA Kits
Figure 3. Molecular detection workflow for hantavirus RNA in clinical samples. (Rio et al., 2024)
References
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| Hantavirus | DEIABL10 | Mouse Anti-Hantavirus ELISA Kit | 48T 2 | Mouse | Qualitative | Serum | Inquiry |
| DEIA2203 | Human Hantavirus Hantaan ELISA Kit | 96T | Human | Qualitative | Serum | Inquiry | |
| DEIA-JY2451 | Mouse Hantavirus (HV) Antibody ELISA Kit | 96T | Mouse | Qualitative | Serum | Inquiry | |
| DEIA-JY2467 | Rat Hantavirus (HV) Antibody ELISA Kit | 96T | Rat | Qualitative | Serum | Inquiry | |
| DEIA2203L | Human Hantavirus Nucleoprotein (HVNP) IgG/IgM ELISA Kit | 96T | Human | Qualitative | Serum | Inquiry | |
| DEIA-NS2660 | Hantavirus IgG ELISA Kit | 96T | Human | Qualitative | Serum or plasma (citrate or heparin) | Inquiry | |
| DEIA-NS2661 | Hantavirus IgM ELISA Kit | 96T | Human | Qualitative | Serum or plasma (citrate or heparin) | Inquiry | |
| DEIA595 | Hantavirus Dobrava/Hantaan IgG/IgM ELISA Kit | 96T | Human | Qualitative | Human serum | Inquiry | |
| DEIA596 | Hantavirus (Puumala) IgG/IgM ELISA Kit | 96T | Human | Qualitative | Serum | Inquiry |
Loading ......
